Balázs Halmos
Impact in
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- COVID-19 and healthcare impacts
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
Papers in
- Oncology 140
- Cancer Immunotherapy and Biomarkers 41
- Lung Cancer Research Studies 26
- Colorectal Cancer Treatments and Studies 23
- COVID-19 and healthcare impacts 22
- HER2/EGFR in Cancer Research 17
-
- Lung Cancer Treatments and Mutations 122
- Lung Cancer Diagnosis and Treatment 32
- Co-authors
- Daniel Geoffrey Tenen (21 shared papers)Susumu S. Kobayashi (16 shared papers)Titus J. Boggon (8 shared papers)Pasi Antero Janne (10 shared papers)Matthew Meyerson (8 shared papers)Bruce Evan Johnson (8 shared papers)Olivier N. Kocher (11 shared papers)Tajhal Dayaram (6 shared papers)
- Journals
- Journal of Thoracic Oncology (23 papers)Journal of Clinical Oncology (15 papers)Annals of Oncology (13 papers)Lung Cancer (12 papers)Clinical Lung Cancer (11 papers)
- Partner nations
- United StatesItalyGermany
In The Last Decade
Balázs Halmos
272 papers receiving 23.6k citations
Balázs Halmos's Hit Papers
Peers
Comparison fields: 5 of 169
- Oncology 12.2k
- Pulmonary and Respiratory Medicine 9.5k
- Otorhinolaryngology 922
- Cancer Research 2.5k
- Immunology 2.0k
Countries citing papers authored by Balázs Halmos
This map shows the geographic impact of Balázs Halmos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Balázs Halmos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Balázs Halmos more than expected).
Fields of papers citing papers by Balázs Halmos
This network shows the impact of papers produced by Balázs Halmos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Balázs Halmos. The network helps show where Balázs Halmos may publish in the future.
Co-authors
The 25 scholars most cited alongside Balázs Halmos, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 291 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib Hit paper breakdown → | 2005 | 3445 |
| 2 | Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 2909 |
| 3 | Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Hit paper breakdown → | 2019 | 2460 |
| 4 | Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Hit paper breakdown → | 2020 | 1331 |
| 5 | Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers Hit paper breakdown → | 2012 | 1103 |
| 6 | Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer Hit paper breakdown → | 2012 | 1053 |
| 7 | Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System Hit paper breakdown → | 2020 | 604 |
| 8 | Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib Hit paper breakdown → | 2006 | 518 |
| 9 | A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407 Hit paper breakdown → | 2020 | 478 |
| 10 | BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations Hit paper breakdown → | 2007 | 442 |
| 11 | 2004 | 437 | |
| 12 | Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study Hit paper breakdown → | 2023 | 354 |
| 13 | Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations Hit paper breakdown → | 2016 | 314 |
| 14 | 2009 | 304 | |
| 15 | 2015 | 286 | |
| 16 | 2005 | 279 | |
| 17 | Seroconversion rates following COVID-19 vaccination among patients with cancer Hit paper breakdown → | 2021 | 266 |
| 18 | 2008 | 252 | |
| 19 | 2005 | 242 | |
| 20 | 2021 | 234 |
About Balázs Halmos
Balázs Halmos is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Pathology and Forensic Medicine, having authored 291 papers that have together received 24.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (122 papers), Cancer Immunotherapy and Biomarkers (41 papers), Lung Cancer Diagnosis and Treatment (32 papers), Cancer Genomics and Diagnostics (27 papers), Lung Cancer Research Studies (26 papers), Colorectal Cancer Treatments and Studies (23 papers), COVID-19 and healthcare impacts (22 papers) and HER2/EGFR in Cancer Research (17 papers). The work is most often cited by research in Oncology (12.2k citations), Pulmonary and Respiratory Medicine (9.5k citations), Otorhinolaryngology (922 citations), Cancer Research (2.5k citations) and Immunology (2.0k citations). Balázs Halmos has collaborated with scholars based in United States, Italy and Germany. Frequent co-authors include Daniel Geoffrey Tenen, Susumu S. Kobayashi, Titus J. Boggon, Pasi Antero Janne, Matthew Meyerson, Bruce Evan Johnson, Olivier N. Kocher, Tajhal Dayaram, Michael J. Eck and Haiying Cheng. Their work appears in journals such as Journal of Thoracic Oncology, Journal of Clinical Oncology, Annals of Oncology, Lung Cancer and Clinical Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.